Generation of infectious Feline Immunodeficiency Virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease

Journal of Virology

Volumn 84, Issue 13, 2010, Pages 6799-6809

  Lin, Ying Chuan ^a   Torbett, Bruce E ^a   Elder, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; DARUNAVIR; LOPINAVIR; PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; FELINE IMMUNODEFICIENCY VIRUS; GROWTH RATE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROGENY; VIROGENESIS; VIRUS INFECTION; VIRUS MUTANT;

AMINO ACID SUBSTITUTION; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CATS; CELL LINE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; INHIBITORY CONCENTRATION 50; PYRIMIDINONES; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; SULFONAMIDES; VIRUS REPLICATION;

FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953307741     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00294-10     Document Type: Article

References (54)

1. Adamson, C. S., K. Salzwedel, and E. O. Freed. 2009. Virus maturation as a new HIV-1 therapeutic target. Expert Opin. Ther. Targets 13:895-908.
2. Anderson, J., C. Schiffer, S.-K. Lee, and R. Swanstrom. 2009. Viral protease inhibitors. Handb. Exp. Pharmacol. 189:85-110.
3. Barragan, P., and D. Podzamczer. 2008. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin. Pharmacother. 9:2363-2375.
4. Beck, Z. Q., L. Hervio, P. E. Dawson, J. H. Elder, and E. L. Madison. 2000. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development. Virology 274:391-401.
5. Beck, Z. Q., Y. C. Lin, and J. H. Elder. 2001. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J. Virol. 75:9458-9469.
6. Beck, Z. Q., G. M. Morris, and J. H. Elder. 2002. Defining HIV-1 protease substrate selectivity. Curr. Drug Targets Infect. Disord. 2:37-50.
7. Bennett, D. E., R. J. Camacho, D. Otelea, D. R. Kuritzkes, H. Fleury, M. Kiuchi, W. Heneine, R. Kantor, M. R. Jordan, J. M. Schapiro, A. M. Vandamme, P. Sandstrom, C. A. Boucher, D. van de Vijver, S. Y. Rhee, T. F. Liu, D. Pillay, and R. W. Shafer. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4:e4724.
8. Brik, A., J. Alexandratos, Y. C. Lin, J. H. Elder, A. J. Olson, A. Wlodawer, D. S. Goodsell, and C. H. Wong. 2005. 1,2,3-Triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors. Chembiochem 6:1167-1169.
9. Brik, A., J. Muldoon, Y. C. Lin, J. H. Elder, D. S. Goodsell, A. J. Olson, V. V. Fokin, K. B. Sharpless, and C. H. Wong. 2003. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. Chembiochem 4:1246-1248.
10. Bühler, B., Y. C. Lin, G. Morris, A. J. Olson, C. H. Wong, D. D. Richman, J. H. Elder, and B. E. Torbett. 2001. Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J. Virol. 75:9502-9508.
11. Dam, E., R. Quercia, B. Glass, D. Descamps, O. Launay, X. Duval, H. G. Krausslich, A. J. Hance, and F. Clavel. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5:e1000345.
12. de Rozières, S., C. H. Swan, D. A. Sheeter, K. J. Clingerman, Y. C. Lin, S. Huitron-Resendiz, S. Henriksen, B. E. Torbett, and J. H. Elder. 2004. Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3. Retrovirology 1:38.
13. DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
14. Elder, J. H., G. A. Dean, E. A. Hoover, J. A. Hoxie, M. H. Malim, L. Mathes, J. C. Neil, T. W. North, E. Sparger, M. B. Tompkins, W. A. Tompkins, J. Yamamoto, N. Yuhki, N. C. Pedersen, and R. H. Miller. 1998. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:797-801.
15. Elder, J. H., and T. R. Phillips. 1995. Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. Adv. Virus Res. 45:225-247.
16. Elder, J. H., and T. R. Phillips. 1993. Molecular properties of feline immunodeficiency virus (FIV). Infect. Agents Dis. 2:361-374. (Pubitemid 24130760)
17. Elder, J. H., M. Sundstrom, S. de Rozières, A. de Parseval, C. K. Grant, and Y. C. Lin. 2008. Molecular mechanisms of FIV infection. Vet. Immunol. Immunopathol. 123:3-13.
18. Fitzgerald, M. C., G. S. Laco, J. H. Elder, and S. B. Kent. 1997. A continuous fluorometric assay for the feline immunodeficiency virus protease. Anal. Biochem. 254:226-230.
19. Giffin, M. J., H. Heaslet, A. Brik, Y. C. Lin, G. Cauvi, C. H. Wong, D. E. McRee, J. H. Elder, C. D. Stout, and B. E. Torbett. 2008. A copper(I)- catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J. Med. Chem. 51:6263-6270.
20. Heaslet, H., Y. C. Lin, K. Tam, B. E. Torbett, J. H. Elder, and C. D. Stout. 2007. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Retrovirology 4:1.
21. Heaslet, H., R. Rosenfeld, M. Giffin, Y. C. Lin, K. Tam, B. E. Torbett, J. H. Elder, D. E. McRee, and C. D. Stout. 2007. Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr. D Biol. Crystallogr. 63:866-875.
22. Henriksen, S. J., O. Prospero-Garcia, T. R. Phillips, H. S. Fox, F. E. Bloom, and J. H. Elder. 1995. Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Curr. Top. Microbiol. Immunol. 202:167-186.
23. Huitron-Resendiz, S., S. De Rozières, M. Sanchez-Alavez, B. Buhler, Y. C. Lin, D. L. Lerner, N. W. Henriksen, M. Burudi, H. S. Fox, B. E. Torbett, S. Henriksen, and J. H. Elder. 2004. Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3. J. Virol. 78:4525-4532.
24. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16:138-145.
25. Johnston, J. C., M. Gasmi, L. E. Lim, J. H. Elder, J. K. Yee, D. J. Jolly, K. P. Campbell, B. L. Davidson, and S. L. Sauter. 1999. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73:4991-5000. (Pubitemid 29246760)
26. Kräusslich, H. G., M. Facke, A. M. Heuser, J. Konvalinka, and H. Zentgraf. 1995. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J. Virol. 69:3407-3419.
27. Kutilek, V. D., D. A. Sheeter, J. H. Elder, and B. E. Torbett. 2003. Is resistance futile? Curr. Drug Targets Infect. Disord. 3:295-309.
28. Laco, G. S., C. Schalk-Hihi, J. Lubkowski, G. Morris, A. Zdanov, A. Olson, J. H. Elder, A. Wlodawer, and A. Gustchina. 1997. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 36:10696-10708.
29. Le, V. D., C. C. Mak, Y. C. Lin, J. H. Elder, and C. H. Wong. 2001. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine. Bioorg. Med. Chem. 9:1185-1195.
30. Lee, S. K., J. Harris, and R. Swanstrom. 2009. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 83:8536-8543.
31. Lee, T., G. S. Laco, B. E. Torbett, H. S. Fox, D. L. Lerner, J. H. Elder, and C. H. Wong. 1998. Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc. Natl. Acad. Sci. U. S. A. 95:939-944.
32. Lee, T., V.-D. Le, D. Lim, Y.-C. Lin, G. M. Morris, A. L. Wong, A. J. Olson, J. H. Elder, and C.-H. Wong. 1999. Development of a new type of protease inhibitors, efficacious against FIV and HIV variants. J. Am. Chem. Soc. 121:1145-1155.
33. Lefebvre, E., and C. A. Schiffer. 2008. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10:131-142.
34. Li, F., R. Goila-Gaur, K. Salzwedel, N. R. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, D. E. Martin, J. M. Orenstein, G. P. Allaway, E. O. Freed, and C. T. Wild. 2003. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U. S. A. 100:13555-13560.
35. Liang, F. S., A. Brik, Y. C. Lin, J. H. Elder, and C. H. Wong. 2006. Epoxide opening in water and screening in situ for rapid discovery of enzyme inhibitors in microtiter plates. Bioorg. Med. Chem. 14:1058-1062.
36. Lin, Y. C., Z. Beck, T. Lee, V. D. Le, G. M. Morris, A. J. Olson, C. H. Wong, and J. H. Elder. 2000. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J. Virol. 74:4710-4720.
37. Lin, Y. C., Z. Beck, G. M. Morris, A. J. Olson, and J. H. Elder. 2003. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J. Virol. 77:6589-6600.
38. Lin, Y. C., A. Brik, A. de Parseval, K. Tam, B. E. Torbett, C. H. Wong, and J. H. Elder. 2006. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system. J. Virol. 80:7832-7843.
39. Luttge, B. G., M. Shehu-Xhilaga, D. G. Demirov, C. S. Adamson, F. Soheilian, K. Nagashima, A. G. Stephen, R. J. Fisher, and E. O. Freed. 2008. Molecular characterization of feline immunodeficiency virus budding. J. Virol. 82:2106-2119.
40. Maguire, M. F., R. Guinea, P. Griffin, S. Macmanus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. Porter, T. Wrin, N. Parkin, M. Tisdale, E. Furfine, C. Petropoulos, B. W. Snowden, and J. P. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76: 7398-7406.
41. Mak, C. C., A. Brik, D. L. Lerner, J. H. Elder, G. M. Morris, A. J. Olson, and C. H. Wong. 2003. Design and synthesis of broad-based mono- and bi-cyclic inhibitors of FIV and HIV proteases. Bioorg. Med. Chem. 11:2025-2040.
42. Mak, C. C., V. D. Le, Y. C. Lin, J. H. Elder, and C. H. Wong. 2001. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3′ residue. Bioorg. Med. Chem. Lett. 11:219-222.
43. Manrique, M. L., M. L. Rauddi, S. A. Gonzalez, and J. L. Affranchino. 2004. Functional domains in the feline immunodeficiency virus nucleocapsid protein. Virology 327:83-92.
44. Martinez-Cajas, J. L., and M. A. Wainberg. 2007. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 76:203-221.
45. Nijhuis, M., N. M. van Maarseveen, and C. A. Boucher. 2007. HIV protease resistance and viral fitness. Curr. Opin. HIV AIDS 2:108-115.
46. Pettit, S. C., M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V. Nantermet, C. A. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
47. Resch, W., N. Parkin, T. Watkins, J. Harris, and R. Swanstrom. 2005. Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J. Virol. 79:10638-10649.
48. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. Biotechniques 8:404-407.
49. Sheng, N., S. C. Pettit, R. J. Tritch, D. H. Ozturk, M. M. Rayner, R. Swanstrom, and S. Erickson-Viitanen. 1997. Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J. Virol. 71:5723-5732. (Pubitemid 27304905)
50. Swanstrom, R., and J. Erona. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.
51. Talbott, R. L., E. E. Sparger, K. M. Lovelace, W. M. Fitch, N. C. Pedersen, P. A. Luciw, and J. H. Elder. 1989. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 86:5743-5747.
52. Watkins, T., W. Resch, D. Irlbeck, and R. Swanstrom. 2003. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 47:759-769.
53. Wensing, A. M., N. M. van Maarseveen, and M. Nijhuis. 2010. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 85:59-74.
54. Wlodawer, A., A. Gustchina, L. Reshetnikova, J. Lubkowski, A. Zdanov, K. Y. Hui, E. L. Angleton, W. G. Farmerie, M. M. Goodenow, D. Bhatt, L. Zhang, and B. M. Dunn. 1995. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat. Struct. Biol. 2:480-488.